Literature DB >> 16741968

Nuclear estrogen receptor targeted photodynamic therapy: selective uptake and killing of MCF-7 breast cancer cells by a C17alpha-alkynylestradiol-porphyrin conjugate.

Narasimha Swamy1, Ajay Purohit, Ana Fernandez-Gacio, Graham B Jones, Rahul Ray.   

Abstract

We hypothesized that over-expression of estrogen receptor (ER) in hormone-sensitive breast cancer could be harnessed synergistically with the tumor-migrating effect of porphyrins to selectively deliver estrogen-porphyrin conjugates into breast tumor cells, and preferentially kill the tumor cells upon exposure to red light. In the present work we synthesized four (4) conjugates of C17-alpha-alkynylestradiol and chlorin e6-dimethyl ester with varying tether lengths, and showed that all these conjugates specifically bound to recombinant ER alpha. In a cellular uptake assay with ER-positive MCF-7 and ER-negative MDA-MB 231 human breast cancer cell-lines, we observed that one such conjugate (E17-POR, XIV) was selectively taken up in a dose-dependent and saturable manner by MCF-7 cells, but not by MDA-MB 231 cells. Furthermore, MCF-7 cells, but not MDA-MB 231 cells, were selectively and efficiently killed by exposure to red light after incubation with E17-POR. Therefore, the combination approach, including drug and process modalities has the potential to be applied clinically for hormone-sensitive cancers in organs where ER is significantly expressed. This could potentially be carried out either as monotherapy involving a photo-induced selective destruction of tumor cells and/or adjuvant therapy in post-surgical treatment for the destruction of residual cancer cells in tissues surrounding the tumor. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741968     DOI: 10.1002/jcb.20955

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells.

Authors:  Kinh-Luan Dao; Rupa R Sawant; J Adam Hendricks; Victoria Ronga; Vladimir P Torchilin; Robert N Hanson
Journal:  Bioconjug Chem       Date:  2012-04-04       Impact factor: 4.774

Review 2.  Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity.

Authors:  María Julia Lamberti; Natalia Belén Rumie Vittar; Viviana Alicia Rivarola
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  Convergent synthesis of a steroidal antiestrogen-mitomycin C hybrid using "click" chemistry.

Authors:  Robert N Hanson; Edward Hua; David Labaree; Richard B Hochberg; Kyle Proffitt; John M Essigmann; Robert G Croy
Journal:  Org Biomol Chem       Date:  2012-09-25       Impact factor: 3.876

Review 4.  Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.

Authors:  Timothy W Corson; Nicholas Aberle; Craig M Crews
Journal:  ACS Chem Biol       Date:  2008-11-21       Impact factor: 5.100

5.  Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy.

Authors:  J Duanmu; J Cheng; J Xu; C J Booth; Z Hu
Journal:  Br J Cancer       Date:  2011-03-22       Impact factor: 7.640

6.  Radiodynamic Therapy Using TAT Peptide-Targeted Verteporfin-Encapsulated PLGA Nanoparticles.

Authors:  Sandhya Clement; Ayad G Anwer; Layla Pires; Jared Campbell; Brian C Wilson; Ewa M Goldys
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.